Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics



p xmlns=””>Curia, formerly AMRI, a leading contract research, advancement and production company, today … Business Wire India

Curia, previously AMRI, a leading agreement production, development and research study organization, today announced it has actually participated in a definitive agreement to obtain LakePharma Inc., a privately held biologics drug discovery, medical research study, development and production organization with operations in California, Massachusetts, and Texas.

This press release features multimedia. View the complete release here:

Established in 2009 in the Bay Area, LakePharma uses its variety of technology platforms to advance jobs from discovery to advancement to manufacturing, namely cell-line advancement, bioexpression systems and viral vector production systems. Practically a quarter of its staff members hold Ph.D. s, bringing know-how in all significant biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, consisting of cell and gene therapy. LakePharma has actually contributed to the development of more than 200 restorative or diagnostic products and served more than 1,500 customers, consisting of 22 of the top 25 worldwide biopharmaceutical business.

After the transaction close, the combined business will provide deep know-how in both little and large particles from drug discovery through drug substance manufacturing, sterilized injectable formulation and fill-finish production. LakePharma’& rsquo; s six centers and 235 workers will sign up with’with Curia & rsquo; s 21 websites and more than 3,100 employees to provide customers an end-to-end partnership in drug process, discovery and solution advancement in addition to drug compound and drug item medical and business manufacturing. Curia just recently revealed it has also signed a definitive agreement to obtain Integrity Bio, a privately held solution and fill-finish company headquartered in Camarillo, California. & ldquo; LakePharma will expand our integrated technique to offer biotech and pharmaceutical business with small and large molecule production, development and research study options, & rdquo; said Curia Chairman & CEO John Ratliff. & ldquo; Funding and innovation in the biotech sector remains strong. Our combined abilities will allow us to partner with our consumers by effortlessly providing LakePharma & rsquo; s multi-modality development’and speed in addition to fill-finish options from Curia. Our contracts with LakePharma and Integrity Bio demonstrate our dedication to expanding and deepening our biologics abilities to help our customers advance from curiosity to cure. & rdquo; Hua Tu, Ph.D., founder and CEO of

LakePharma, stated: & ldquo; LakePharma is pleased to join the Curia family. Over the last 12 years, we have actually constructed a strong brand as ' The Biologics Company, ' a gifted and devoted worker team, and a loyal and helpful client base. We are delighted to sign up with Curia’& rsquo; s international network, including industrial manufacturing abilities, in providing end-to-end integrated biologics services to our pharma and biotech customers.”


p xmlns=””>& rdquo; RBC Capital Markets, LLC is working as special monetary advisor to Curia and Nelson Mullins Riley & & Scarborough LLP is functioning as Curia’& rsquo; s legal counsel. Goldman Sachs & Co. LLC is serving as monetary adviser to LakePharma, and Fenwick & West LLP is functioning as LakePharma & rsquo; s legal counsel. The transaction, which undergoes popular and basic closing conditions, is anticipated to close in the third quarter. Regards to the arrangement have not been divulged.

About Curia
Curia, formerly AMRI, is a leading agreement development, manufacturing and research study organization providing services and products from R&D through commercial manufacturing to biopharmaceutical and pharmaceutical clients. Curia’& rsquo; s 3,100 employees at 21 locations throughout the U.S., Europe and Asia help its consumers advance from curiosity to treat. Discover more at

About LakePharma
LakePharma is a U.S.-based biologics CRDMO with operations in California, Texas, and Massachusetts. This biotech company focuses on the production and examination of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates while providing integrated options bridging discovery, engineering, gmp, and development production. LakePharma has contributed to the development of 200+ diagnostic or therapeutic items and aims to establish hundreds more. Discover more at


p id=”mmgallerylink” xmlns=””> View source version on